Merck & Co.(MRK)

RAHWAY, NJPharmaceutical4 H-1B visas (FY2023)

Focus: Merck & Co. is a diversified Big Pharma leader with $60.1B in FY2025 revenue, competing globally across oncology, vaccines, infectious disease, cardiovascular, and immunology. The company operates 69,000 employees and maintains significant R&D infrastructure with 51% R&D intensity.

Oncology Vaccines Infectious Disease Cardiovascular

Profile data last refreshed 4h ago · AI intelligence enriched 1mo ago

Funding Stage

PUBLIC

Employees

69,000

Open Jobs

1056+531 this month

Hot — 2009 jobs added in 30d

Net +531 (2009 new, 1478 removed). Aggressive expansion phase.

4 recent layoff filings (12 mo) — 550 affected

9/1/2026 — Rahway, NJ · 54 affected · Layoff
6/1/2026 — Rahway, NJ · 88 affected · Layoff
11/1/2025 — Rahway, NJ · 204 affected · Layoff
+1 more

Source: state DOL filings via Big Local News

Should You Work at Merck & Co.?

AI assessment

Merck offers career stability and scientific depth in oncology/vaccines, but the patent cliff crisis and concurrent restructuring create near-term job security risk; best suited for candidates with 2+ year horizon or specialized expertise in growth areas.

Why Work Here

Strong R&D investment ($30.5B in FY2025) with active pipeline across oncology (pembrolizumab in Phase 3 gastric cancer, Phase 1/2 melanoma) and vaccines, offering deep scientific careers.

Data completeness

7/9 — Strong

Company HealthWatch

Pipeline

Early-stage

50 total

LOE Risk

9 imminent

BRIDION

Hiring

Slowing

Jobs decreasing

Key Products

JANUVIA

Type 2 diabetes mellitus

$4.1B

LOE Approaching

Help build intelligence for Merck & Co.

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

JANUMET

Type 2 diabetes mellitus

$799M

LOE Approaching2.3yr

Combination therapy losing exclusivity January 2029; contributes ~1.3% of revenue but demonstrates reliance on single therapeutic class.

JANUMET XR

Type 2 diabetes mellitus

$392M

LOE Approaching0.6yr

Extended-release formulation losing exclusivity May 2027; represents portfolio diversification attempt within same class.

BELSOMRA

Insomnia (orexin receptor antagonist)

$161M

Peak6.6yr

Peak-phase asset with 7+ years of exclusivity remaining; provides stability amid diabetes portfolio erosion.

LOSARTAN POTASSIUM

Hypertension

$143M

Post-LOE

Off-patent generic cardiovascular agent generating stable but non-growth revenue.

ISENTRESS

HIV-1 infection

$131M

Peak2.9yr

Integrase inhibitor in peak phase with September 2029 LOE; infectious disease franchise anchor.

DIFICID

Clostridioides difficile infection

$127M

LOE Approaching1.3yr

Specialty antibiotic facing January 2028 patent expiration; represents niche infectious disease play.

DULERA

Asthma

$117M

LOE Approaching

Combination inhaler in mature lifecycle; limited growth trajectory.

PF-03084014

Neoplasm

N/A

Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage

Nasopharyngeal Carriage of S. Pneumoniae

N/A

Real time PCR

CMV

N/A

Functional Living Index - Emesis

Vomiting

N/A

non-interventional

Antiemetic Therapy

N/A

Clinical Trials (3)

NCT01125475A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects

N/A

NCT02921035Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

HPV vaccine

Evaluating Attitudes Toward HPV Vaccinations in Pharmacies

N/A

Clinical Trials (3)

NCT02968420Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine

Phase 4

NCT02937155In the Era of the HPV Vaccine, What Are The Current HPV Subtypes Contributing to High Grade Cervical Dysplasia, Adenocarcinoma in Situ, and Early Cervical Cancer?

Disease Management Assessment

Chemotherapy Induced Nausea and Vomiting

N/A

Post Pandemic Pneumococcal Carriage Among Children and Adults

Pneumococcal Carriage

N/A

Hanyang University Medical Center Arthritis Network

Arthritis, Rheumatoid

N/A

Individualized Feedback

HIV Prevention

N/A

Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.

Hip Fracture

N/A

Indinavir sulfate

HIV Infections

N/A

Clinical Trials (1)

NCT00002410A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

Phase 3

Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis

ANCA Associated Vasculitis

N/A

easypod™

Growth Disorders

N/A

Clinical Trials (2)

NCT01582334To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Argentina

N/A

NCT00738205Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector

N/A

A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects

HIV

N/A

Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia

Low CETP Activity

N/A

The Hyfrecator ® 2000 Electrosurgical System

Anal Dysplasia

N/A

Cancer care delivery

Care Delivery

N/A

ROTATEQ™ Post-Marketing Surveillance in the Philippines

Rotavirus Infections

N/A

Microbiology and Clinical Outcome of Pneumonia

Pneumonia

N/A

Vaccine Confidence Study Among Historically Marginalized Racial and Ethnic Groups

Vaccine Hesitancy

N/A

GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)

Papillomavirus Infections

N/A

Non Standard of Care blood samples collection

Haemato-oncological Paediatric Patients Under Intensive Chemotherapy

N/A

Message X Onsite/Offsite Vaccination

Human Papilloma Virus, Male

N/A

VARIVAX™

Varicella

N/A

Biopsy

Pruritus

N/A

Clinical Trials (1)

NCT05405686Effect of LH Supplementation on the Endometrial Gene Expression Profile in Poor Ovarian Responders

Phase 4

Screening and Brief Intervention

Medication Adherence

N/A

quadrivalent human papillomavirus vaccine

Quadrivalent HPV Vaccine

N/A

Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College

Human Papillomavirus

N/A

Long Term Follow up Study of Predictive Markers in GHD and TS Children

Growth Hormon Deficiency

N/A

Clinical Trials (1)

NCT00699855Long Term Follow up Study of Predictive Markers in GHD and TS Children

N/A

Track bleeding patterns before and after implant

Contraception

N/A

PREMIUM, Observational Study

First Line WT KRAS mCRC

N/A

Clinical Trials (1)

NCT01756625PREMIUM, Observational Study

N/A

Retrospective Evaluation of Patient Failure to Follow-up at a Community Based Headache Clinic

Headache

N/A

Clinical Outcomes and Cost of Gram Negative Bacteremia

Gram-negative Bacteremia

N/A

ARQ 092

Proteus Syndrome

N/A

Surveillance of Non-invasive Streptococcus Pneumoniae Infections in Belgium

Pneumonia

N/A

Lipid Profile and Diabetes Mellitus in People With HIV

HIV Infections

N/A

Clinical Trials (1)

NCT04125784Lipid Profile and Diabetes Mellitus in People With HIV

N/A

Questionnaire

Lifestyle Factors

N/A

Clinical Trials (3)

NCT04195399A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

Phase 2

NCT01141751An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy

SARS-CoV-2 Antibody Analysis

Coronavirus Infection

N/A

Pre-Test Intervention

Cancer

N/A

MMR vaccine

Measles

N/A

Lipid Management in Clinical Practice (MK-0524A-115)

Lipid Metabolism Disorder

N/A

Vancomycin-Associated Nephrotoxicity

Nephrotoxicity

N/A

Clinical Trials (1)

NCT01216540Vancomycin-Associated Nephrotoxicity

N/A

Tetanus & Diphtheria booster vaccine

Vaccine Response Impaired

N/A

Recombinant-follicle stimulating hormone

Multifollicular Stimulation

N/A

Clinical Trials (1)

NCT01080729An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen

N/A

Pneumococcal Nasopharyngeal and Oropharyngeal Carriage in Adults

Preference, Patient

N/A

The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients

HIV

N/A

Colon resection

Diverticulitis

N/A

Interview Prep Quick Facts

Portfolio: 491 approved products, 116 clinical trials

Top TAs: Oncology, Neurology, Immunology

H-1B (2023): 4 approvals

Publications: 194 in PubMed

SEC Filings: 2 available

Open Roles: 1056 active jobs

Portfolio Health

Pre-Launch69 (14%)

Launch3 (1%)

Growth2 (0%)

Peak35 (7%)

LOE Approaching232 (47%)

Post-LOE150

Therapeutic Area Focus

Oncology

122 marketed250 pipeline

Neurology

113 marketed81 pipeline

Immunology

115 marketed32 pipeline

Respiratory

102 marketed17 pipeline

Financials (FY2025)

Revenue

$60.1B1%

R&D Spend

$30.5B(51%)125%

Net Income

$365M

Hiring Trend

Actively Hiring

1056

Open Roles

+449

Added

-365

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (9)

2026-06

88 employees affected— Rahway, NJ

2025-11

204 employees affected— Rahway, NJ

2025-11

204 employees affected— Rahway, NJ

2025-08

58 employees affected— Rahway, NJ

2007

$799M Part D

LOE: 2029

2011

$127M Part D

LOE: 2028 (17mo)

CLINICAL PHARMACOLOGY The primary action of beta-adrenergic agonist drugs, including albuterol, is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'- adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP) in beta-adrenergic cells. The cyclic AMP thus formed mediates the cellular responses. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta 2 -receptors in the human heart existing in a concentration between 10% and 50%. The precise function of these receptors has not been established (see ). In controlled clinical trials, albuterol has been shown to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects. Controlled clinical studies and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or ECG changes. Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol- O -methyl transferase. Preclinical Intravenous studies in rats with albuterol sulfate have demonstrated that albuterol crosses the blood-brain barrier and reaches brain concentrations amounting to approximately 5% of the plasma concentrations. In structures outside the blood-brain barrier (pineal and pituitary glands), albuterol concentrations were found to be 100 times those in the whole brain. Studies in laboratory animals (minipigs, rodents, and dogs) have demonstrated the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta-agonists and methylxanthines are administered concurrently. The clinical significance of these findings is unknown. Pharmacokinetics Albuterol is rapidly and well absorbed following oral administration. In studies involving normal volunteers, the mean steady-state peak and trough plasma levels of albuterol were 6.7 and 3.8 ng/mL, respectively, following dosing with a 2 mg albuterol tablet every 6 hours and 14.8 and 8.6 ng/mL, respectively following dosing with a 4 mg albuterol tablet every 6 hours. Maximum albuterol plasma levels are usually obtained between 2 and 3 hours after dosing, and the elimination half-life is 5 to 6 hours. These data indicate that albuterol

NCT02888197Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

N/A

NCT06915779Long Term Follow-up of HPV Vaccine in HIV (CTN 236)

N/A

NCT02072564Influence of Diet and Lifestyle Factors on the Results of the IVF

N/A

79 marketed38 pipeline

Cardiovascular

70 marketed32 pipeline

Hematology

71 marketed9 pipeline

Metabolic Diseases

38 marketed18 pipeline

2025-03

93 employees affected— Jersey City, NJ

2025-03

93 employees affected— Jersey City, NJ

2024-04

310 employees affected— Jersey City, NJ

2024-02

— Rahway, NJ

1 active drug shortage

Merck filed 9 WARN Act notices (Feb 2024–Jun 2026) affecting at least 1,117 employees, with largest hit (310 workers, April 2024) at Jersey City cited as 'operational efficiency' and subsequent Rahway rounds (Feb 2024) labeled 'R&D restructuring.'

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Merck & Co.(MRK)

Should You Work at Merck & Co.?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (72)

Key Products by Revenue

Other Products (37)

Pipeline & Clinical Trials

Recent News · Merck & Co.(10)

Open Jobs (1056)

Principal Scientist, Translational Clinical Biomarkers

Operations Lead (Shop Floor Supervisor)

LATAM, Director Market Access Pipeline -Oncology

Principal Scientist, Drug Discovery

Cardiovascular Disease Specialist – Northeast PA District

Director, Global Scientific Content Oncology (Breast & Gynecological Malignancies)

Regional Medical Scientific Director (RMSD) - Gynecologic Malignancies (IL, MO, AR, TN, KY)

Principal Scientist (Director), Translational Medicine - Cardiovascular

Principal Scientist, Translational Clinical Biomarkers - Hematology/Oncology

Specialist, Engineering

Sr. Specialist, Operational Readiness Lead

Utility Techn.-Stationary Engi

Principal Scientist, Pharmacokinetics

Senior Principal Scientist, Clinical Research, Thoracic Malignancies

Assoc Director, Global Procurement - Primary Market Research

Associate Director, Commercial Capabilities - Human Health Learning & Development (Hybrid - Upper Gwynedd, PA)

Executive Director, Marketing & Campaign Effectiveness

Scientist, Engineering

Global Dairy Technology Support Specialist

Associate Director, Planning & Scheduling - Onsite

Data Manager, ACDS Informatics

Specialist, Engineering

Associate Specialist, Clinical Data Management - Hybrid

Associate Specialist, Engineering

Dir.,Technical Project Management

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (9)

Research Publications(10)